Kiora Pharmaceuticals Return On Equity vs. Number Of Shares Shorted

KPRX Stock  USD 3.31  0.11  3.22%   
Based on Kiora Pharmaceuticals' profitability indicators, Kiora Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in December. Profitability indicators assess Kiora Pharmaceuticals' ability to earn profits and add value for shareholders.
For Kiora Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Kiora Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Kiora Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Kiora Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Kiora Pharmaceuticals over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis.
For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiora Pharmaceuticals. If investors know Kiora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiora Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kiora Pharmaceuticals is measured differently than its book value, which is the value of Kiora that is recorded on the company's balance sheet. Investors also form their own opinion of Kiora Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiora Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiora Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiora Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kiora Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kiora Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiora Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Kiora Pharmaceuticals Number Of Shares Shorted vs. Return On Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Kiora Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Kiora Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Kiora Pharmaceuticals is currently regarded as number one stock in return on equity category among its peers. It is rated below average in number of shares shorted category among its peers making about  340,891  of Number Of Shares Shorted per Return On Equity. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kiora Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Kiora Number Of Shares Shorted vs. Return On Equity

Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Kiora Pharmaceuticals

Return On Equity

 = 

Net Income

Total Equity

 = 
0.14
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Kiora Pharmaceuticals

Shares Shorted

 = 

Shorted by Public

+

by Institutions

 = 
46.67 K
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.

Kiora Number Of Shares Shorted Comparison

Kiora Pharmaceuticals is currently under evaluation in number of shares shorted category among its peers.

Kiora Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Kiora Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Kiora Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Kiora Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Kiora Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah. Kiora Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.

Kiora Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Kiora Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Kiora Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Kiora Pharmaceuticals' important profitability drivers and their relationship over time.

Use Kiora Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kiora Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kiora Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Kiora Pharmaceuticals Pair Trading

Kiora Pharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Kiora Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kiora Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kiora Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kiora Pharmaceuticals to buy it.
The correlation of Kiora Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kiora Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kiora Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kiora Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Kiora Pharmaceuticals position

In addition to having Kiora Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run ISP Thematic Idea Now

ISP
ISP Theme
Internet Service Providers (ISP) companies and IT providers specializing in internet technologies. The ISP theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize ISP Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Kiora Stock Analysis

When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.